EPA vs DHA: Omega-3 Dosing Guide

Walk into any supplement aisle and you'll find omega-3 products with numbers that look precise — "EPA 540 mg, DHA 360 mg" — as if the body divides them neatly into two columns. It doesn't. EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) are structurally distinct, metabolized differently, and concentrated in different tissues. They don't do the same things, and the doses that matter for one may not matter for the other.

This article examines what the research actually says about each — not what the labels imply.

What EPA and DHA Are

EPA and DHA are long-chain omega-3 polyunsaturated fatty acids found primarily in marine sources — fatty fish, fish oil, and algal oil. Both are 20- and 22-carbon chains respectively, with multiple double bonds that make them highly unsaturated and biologically active.

Humans can technically synthesize EPA and DHA from alpha-linolenic acid (ALA), the short-chain omega-3 found in flaxseed, chia, and walnuts. But conversion is inefficient. Estimates suggest less than 8% of ALA is converted to EPA, and less than 0.5% reaches DHA — meaning diet or supplementation is the practical route to meaningful tissue levels.

The distinction between EPA and DHA matters because they partition differently. DHA is the predominant omega-3 in the brain (constituting roughly 97% of brain omega-3s) and retina, where it supports neuronal membrane fluidity and synaptic function. EPA is found at much lower concentrations in the brain but appears more influential in cardiovascular tissues and in modulating inflammatory signaling — it competes with arachidonic acid for the same enzymatic pathways, reducing production of pro-inflammatory eicosanoids.

Both serve as precursors to specialized pro-resolving mediators — resolvins, protectins, and maresins — that actively resolve inflammation rather than simply blocking it. EPA produces E-series resolvins; DHA produces D-series resolvins, protectins, and maresins. These lipid mediators are part of why researchers suspect omega-3 effects extend beyond triglyceride lowering.

What the Research Shows

Cardiovascular Outcomes: The EPA Story

The strongest omega-3 cardiovascular data come from EPA — specifically, high-dose purified EPA. The REDUCE-IT trial (Bhatt et al., 2019) randomized 8,179 patients with elevated triglycerides (135–499 mg/dL) and established cardiovascular disease or diabetes plus risk factors to 4 g/day of icosapent ethyl (a purified EPA ethyl ester) or placebo. Over a median 4.9 years, the EPA group experienced a 25% relative risk reduction in the primary composite endpoint of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina (HR 0.75; 95% CI 0.68–0.83; absolute risk reduction 4.8%).

Whether those results translate to lower doses or EPA+DHA combinations is less clear. A 2024 Bayesian reanalysis of the VITAL trial (Hamaya & Cook, 2024) — which tested 840 mg/day EPA+DHA in 25,871 primary-prevention participants — found a 99.7% probability that supplementation reduced coronary artery disease (posterior HR 0.88–0.93) and a 99.6% probability it reduced myocardial infarction (HR 0.82–0.90). The absolute effects, however, were small in this low-risk population: roughly 1 fewer MI per 1,000 person-years.

A recent umbrella review of meta-analyses (2025) reinforces the pattern: EPA monotherapy consistently outperforms EPA+DHA combinations for myocardial infarction and revascularization outcomes, and effects are most apparent in secondary prevention and in people with elevated triglycerides.

Cognitive Function: DHA in the Spotlight

DHA's role in brain structure — it literally constitutes 10–15% of cortical fatty acids — has made it the focus of cognitive research. The evidence, however, is nuanced and depends heavily on when supplementation begins relative to cognitive decline.

A 2024 systematic review and dose-response meta-analysis of 24 studies (9,660 participants) published in Clinical Nutrition (Shahinfar et al., 2024) found that omega-3 supplementation produced significant improvements in attention (SMD 0.98), perceptual speed (SMD 0.50), and global cognitive abilities (SMD 1.08) at doses exceeding 500 mg/day. But the review noted a striking pattern: effects were strongest in regions where participants' baseline EPA+DHA levels were not already depleted, and the dose-response relationship was nonlinear — episodic memory actually decreased at lower doses before improving at higher ones.

The stage of cognitive decline matters critically. A 2023 narrative review of 15 RCTs in cognitively healthy adults over age 55 found that seven reported benefits while eight did not. In people with mild cognitive impairment (MCI), DHA supplementation showed more consistent effects. In people with established Alzheimer's disease, it showed none. This pattern suggests omega-3s may support cognitive resilience when neurodegeneration is early, but cannot reverse established pathology.

Inflammation: Broad and Consistent Effects

If there's one domain where the omega-3 evidence converges, it's inflammation. A 2025 systematic review and meta-analysis of 96 randomized controlled trials (Morshedzadeh et al., 2025) found that EPA+DHA supplementation (1–3 g/day) significantly reduced C-reactive protein, tumor necrosis factor-alpha, and interleukin-6. The effect was stronger in people with pre-existing health conditions than in healthy controls, and EPA:DHA ratios below 1.0 (more DHA) produced the greatest cytokine reductions, while ratios at or above 1.0 (more EPA) were best for lowering arachidonic acid levels.

These anti-inflammatory effects are dose-dependent but appear to plateau — benefits were observed between 1 and 3 g/day, with no clear advantage beyond 3 g/day for inflammatory markers alone. The clinical translation of reduced inflammatory biomarkers into reduced disease risk remains an area of active investigation.

Dosing & Practical Considerations

Dose Range	Evidence Strength	Primary Outcomes
<1 g/day EPA+DHA	Low — Trial Sequential Analysis confirms futility for mortality benefit at these doses	May modestly reduce cardiac mortality (RR 0.55 at ~2 g equivalent); no significant cardiovascular event reduction below 1 g/day
1–2 g/day EPA+DHA	Moderate — benefits for cardiac events in secondary prevention	Reductions in cardiac mortality, triglyceride lowering; cognitive benefits appear above 500 mg/day
≥3 g/day (especially EPA-dominant)	Strongest — REDUCE-IT level evidence for EPA monotherapy	25% relative risk reduction in major cardiovascular events (EPA 4 g/day); revascularization reduction; most data from high-risk populations

The Omega-3 Index

Dietary intake of EPA and DHA is an imperfect proxy for what reaches tissues. The omega-3 index — the percentage of EPA + DHA in red blood cell membranes — provides a more direct measure. A 2022 review of the evidence suggests an omega-3 index of 8–12% is associated with the lowest cardiovascular risk, while an index below 4% is associated with the highest. Achieving an index of 8% typically requires 1–2 g/day of EPA+DHA in most people, though individual variability is substantial due to differences in absorption, metabolism, and baseline status.

EPA:DHA Ratio

There is no universally optimal EPA:DHA ratio. The data suggest the target should be driven by the outcome of interest: EPA-dominant formulations (or EPA alone) for cardiovascular risk reduction, and DHA-inclusive formulations for cognitive support. Most conventional fish oil supplements supply EPA and DHA in a roughly 1.5:1 to 2:1 ratio, which is a reasonable compromise for general health — though the research increasingly suggests that specific clinical goals may benefit from more targeted ratios.

Triglyceride Form Matters

Omega-3s come in three common forms: ethyl esters (synthetic), triglycerides (the natural form found in fish), and phospholipids (as in krill oil). Studies suggest triglyceride-form omega-3s are absorbed approximately 30–50% more efficiently than ethyl esters under fasting conditions, though the difference narrows when taken with a fat-containing meal. For practical purposes: taking any form with food that includes dietary fat improves absorption, and re-esterified triglyceride forms appear to offer the best bioavailability per gram consumed.

Safety & Interactions

Omega-3 supplementation is generally well-tolerated, with gastrointestinal side effects (fishy burps, mild nausea) being the most common complaint. At doses above 3 g/day, a modest prolongation of bleeding time has been observed due to EPA's inhibition of platelet aggregation — which is mechanistically consistent with reduced cardiovascular events but warrants caution in people taking anticoagulant medications or scheduled for surgery.

The U.S. Food and Drug Administration has generally recognized as safe (GRAS) intakes of up to 3 g/day of EPA+DHA combined, though prescribers routinely use higher doses (particularly 4 g/day of icosapent ethyl) under medical supervision. The European Food Safety Authority similarly considers supplemental intakes up to 5 g/day as safe for adults.

Key considerations:

• Blood thinning: Omega-3s above 3 g/day may increase bleeding risk, particularly in combination with warfarin, aspirin, or other anticoagulants. Discuss with a physician if you're on these medications.
• Oxidation: Omega-3 oils are susceptible to oxidation. Rancid fish oil may increase lipid peroxidation rather than reduce it. Look for products that disclose peroxide values and preferably include antioxidants like vitamin E to prevent oxidation.
• Atrial fibrillation: A signal of increased atrial fibrillation risk has emerged from high-dose omega-3 trials (particularly REDUCE-IT, where the rate was 5.3% vs. 3.9% in placebo). The absolute risk increase is small but consistent across high-dose studies, and the risk-benefit calculus may differ by individual cardiovascular profile.
• Heavy metals: Reputable fish oil products undergo molecular distillation to remove mercury, PCBs, and dioxins. Third-party testing (IFOS, USP, or NSF certification) provides independent verification.

Bottom Line

Omega-3s are among the most studied supplements in existence, and the evidence points to real but modest effects — not a panacea. EPA and DHA have overlapping but distinct roles, and the dose, ratio, and individual's baseline status all matter more than the marketing suggests. For cardiovascular outcomes, the evidence leans EPA-heavy and dose-dependent, with the strongest data at 3–4 g/day in high-risk populations. For cognitive support, DHA appears central but the effects are most consistent in early-stage decline, not prevention in healthy adults. A reasonable starting point for general health is 1–2 g/day of combined EPA+DHA, ideally informed by an omega-3 index measurement, taken with food, and from a third-party tested source.

Evoria Health's approach to supplementation is built on this kind of evidence — clinically studied doses, transparent labeling, and formulations designed around what the data actually show rather than what sounds good on a label. Our supplement system is designed to provide meaningful quantities of ingredients at the doses that were actually studied, across three products targeting distinct biological needs.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. The information in this article is for educational purposes only and does not constitute medical advice. Consult with a healthcare provider before starting any supplement regimen, particularly if you are taking medications or have a pre-existing health condition.

---

Ready to put the science into practice?

Evoria's Daily Essentials provides a comprehensive foundation of essential nutrients to support whole-body balance and vitality. Shop Daily Essentials →

References

1. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380(1):11-22.
2. Hamaya R, Cook NR. A Bayesian Analysis of the VITAL Trial: Effects of ω-3 Fatty Acid Supplementation on Cardiovascular Outcomes. J Am Heart Assoc. 2024;13(7):e033905.
3. Shahinfar H, Amini MR, Payandeh N, et al. A systematic review and dose-response meta-analysis of omega-3 fatty acids and cognitive function. Clin Nutr. 2024;43(5):1189-1203.
4. Morshedzadeh N, Rahimlou M, Shahrokh S, et al. Effects of omega-3 fatty acids on inflammatory biomarkers: a systematic review and meta-analysis of 96 randomized controlled trials. Prostaglandins Leukot Essent Fatty Acids. 2025;202:102671.
5. Khan SU, Lone AN, Khan MS, et al. Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis. EClinicalMedicine. 2021;38:100997.

Frequently Asked Questions

What's the difference between EPA and DHA?

EPA and DHA are both long-chain omega-3 fatty acids, but they differ in structure (EPA has 20 carbons, DHA has 22) and function. EPA appears more influential for cardiovascular protection and reducing inflammation via competition with arachidonic acid. DHA is the predominant omega-3 in the brain and retina, where it supports neuronal membrane structure and synaptic signaling. Both produce specialized pro-resolving mediators that actively resolve inflammation, but via different pathways (E-series resolvins from EPA; D-series resolvins, protectins, and maresins from DHA).

How much EPA and DHA should I take daily?

There is no single optimal dose. A reasonable general-health starting point is 1–2 g/day of combined EPA+DHA. For cardiovascular risk reduction in high-risk populations, higher EPA-dominant doses (3–4 g/day) show the strongest evidence. Measuring your omega-3 index (target: 8–12%) provides a more personalized guide than population averages.

Is fish oil better than algal oil?

Both can be effective. Fish oil naturally contains both EPA and DHA, typically in a 1.5:1 to 2:1 ratio. Algal oil is the primary source of DHA used by fish themselves (they get it from algae) and is suitable for vegetarians and vegans. Algal oils typically contain more DHA than EPA. The key is the total EPA+DHA content and the form (triglyceride vs. ethyl ester), not the source organism.

Can I take too much omega-3?

Yes. Doses above 3 g/day are associated with a modest increase in bleeding risk due to EPA's antiplatelet effects. High-dose trials have also identified a small but consistent increase in atrial fibrillation risk (approximately 1–2 additional cases per 1,000 person-years at 4 g/day). The FDA considers up to 3 g/day generally safe, but higher doses should be taken under medical supervision.

Does omega-3 supplementation help with brain fog or focus?

The evidence is mixed. Dose-response meta-analyses show improvements in attention and processing speed at doses above 500 mg/day, but effects are modest and the quality of evidence ranges from low to moderate. Benefits appear more consistent in people with mild cognitive impairment than in healthy adults. If your diet is low in fatty fish and your omega-3 index is below 4%, supplementation may be more likely to produce noticeable cognitive effects.